Clinical Trials Logo

Recurrent Liposarcoma clinical trials

View clinical trials related to Recurrent Liposarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04213794 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

TOASTIT
Start date: November 8, 2019
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to treatment (refractory), or has come back (recurrent). Heated intra-peritoneal chemotherapy is a procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity. Chemotherapy drugs, such as doxorubicin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more cells.

NCT ID: NCT02357810 Completed - Clinical trials for Recurrent Osteosarcoma

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Start date: March 21, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01653028 Completed - Clinical trials for Recurrent Adult Soft Tissue Sarcoma

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Start date: August 22, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well alisertib works in treating patients with sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.